BYRAYIC Trademark

Trademark Overview


On Thursday, January 12, 2017, a trademark application was filed for BYRAYIC with the United States Patent and Trademark Office. The USPTO has given the BYRAYIC trademark a serial number of 87299351. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 3, 2020. This trademark is owned by Allergan Sales, LLC. The BYRAYIC trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable...
byrayic

General Information


Serial Number87299351
Word MarkBYRAYIC
Filing DateThursday, January 12, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 3, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 2, 2017

Trademark Statements


Goods and ServicesPharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, January 19, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Sales, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressMadison, NJ 07940

Party NameAllergan Sales, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressIrvine, CA 92612

Trademark Events


Event DateEvent Description
Monday, August 3, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, August 3, 2020ABANDONMENT - NO USE STATEMENT FILED
Friday, December 27, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 26, 2019EXTENSION 5 GRANTED
Tuesday, December 17, 2019EXTENSION 5 FILED
Thursday, December 26, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, December 17, 2019TEAS EXTENSION RECEIVED
Wednesday, March 20, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 18, 2019EXTENSION 4 GRANTED
Monday, March 18, 2019EXTENSION 4 FILED
Monday, March 18, 2019TEAS EXTENSION RECEIVED
Tuesday, November 13, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 9, 2018EXTENSION 3 GRANTED
Friday, November 9, 2018EXTENSION 3 FILED
Friday, November 9, 2018TEAS EXTENSION RECEIVED
Saturday, June 16, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 14, 2018EXTENSION 2 GRANTED
Thursday, June 14, 2018EXTENSION 2 FILED
Thursday, June 14, 2018TEAS EXTENSION RECEIVED
Friday, November 17, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 15, 2017EXTENSION 1 GRANTED
Wednesday, November 15, 2017EXTENSION 1 FILED
Wednesday, November 15, 2017TEAS EXTENSION RECEIVED
Tuesday, June 27, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 2, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 2, 2017PUBLISHED FOR OPPOSITION
Wednesday, April 12, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 22, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, March 11, 2017ASSIGNED TO EXAMINER
Thursday, January 19, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, January 16, 2017NEW APPLICATION ENTERED IN TRAM